Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
71.50    0.50 (0.70%)
Bid:
71.20
Ask:
74.00
Spread: 2.80 (3.933%)
Market Cap: £684.32m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

CFO retirement

14 Apr 2023 07:01

RNS Number : 1908W
Dr. Martens PLC
14 April 2023
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

 

14 April 2023

Dr. Martens plc

("the Company")

 

CFO retirement

 

Dr. Martens Plc today announces that, with agreement of the Board, Jon Mortimore has decided to retire from his role as Chief Financial Officer (CFO) of the Company. Jon will continue in his role until a successor is in place to ensure a smooth transfer of responsibilities.

The Company is commencing an external search for Jon's successor.

Jon joined the company in April 2016. During his seven years at Dr. Martens, Jon has been instrumental in delivering the Company's transition from a family-run company to a listed PLC, overseeing revenue growth from £230m to £1bn, as well as playing an integral role in the Company's initial public offering (IPO) in January 2021.

Paul Mason, Dr. Martens Chair said "On behalf of the Board, I would like to thank Jon for his central role in driving the strong growth and strategic development of Dr. Martens over the last seven years. His knowledge of the business and understanding of the Company's value drivers have played a key part in helping develop the business during this period. We also want to thank him for his careful stewardship of the finance function, in particular during the pandemic period, which is testament to his dedication and exceptional hard work. We wish him well in his retirement."

Jon Mortimore, CFO added "I am proud of the progress that Dr. Martens has achieved during my time as CFO since 2016 and I look forward to seeing further growth and success in the years to come. This is a great company with an incredible brand and passionate people, and I believe it has a very exciting long-term future ahead of it. I will be retiring once my successor is in place but until then, I will continue to support Dr. Martens in my role as CFO."

 

Enquiries

Investors and analysts

Mark Blythman, Interim Director of Investor Relations Mark.Blythman@drmartens.com +44 7570 871207

Beth Callum, Senior Investor Relations Analyst Beth.callum@drmartens.com +44 203 995 2644

 

Press

Maitland +44 207 379 5151

Clinton Manning +44 7711 972662

 

Gill Hammond, Director of Communications +44 7384 214248

 

This announcement contains inside information. The person responsible for arranging the release of this announcement on behalf of the Company is Emily Reichwald, Chief People and Sustainability Officer and Company Secretary.

 

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Produced originally for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, "Docs" or "DM's" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. The Company is a constituent of the FTSE 250 index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAIJMLTMTABBPJ
Date   Source Headline
8th Jun 202612:26 pmRNSHolding(s) in Company
5th Jun 202610:43 amRNSAdmission to Trading
2nd Jun 20269:00 amRNSDirector/PDMR Shareholding
2nd Jun 20269:00 amRNSAnnual Financial Report
2nd Jun 20268:22 amRNSTotal Voting Rights
27th May 20267:00 amRNSDirectorate change
19th May 20267:00 amRNSEBT Share Purchase
19th May 20267:00 amRNSFY26 Results
14th May 20268:53 amRNSDirector/PDMR Shareholding
1st May 20267:00 amRNSHolding(s) in Company
30th Apr 20268:31 amRNSTotal Voting Rights
29th Apr 20267:00 amRNSHolding(s) in Company
16th Apr 20267:00 amRNSDirector/PDMR Shareholding
15th Apr 20269:50 amRNSDirector/PDMR Shareholding
10th Apr 20261:46 pmRNSDirector/PDMR Shareholding
8th Apr 20267:00 amRNS-RAppointment of Market General Managers
31st Mar 20269:53 amRNSTotal Voting Rights
20th Mar 20267:00 amRNSHolding(s) in Company
13th Mar 20262:03 pmRNSDirector/PDMR Shareholding
27th Feb 202611:04 amRNSTotal Voting Rights
13th Feb 202610:49 amRNSDirector/PDMR Shareholding
30th Jan 202611:15 amRNSTotal Voting Rights
29th Jan 20267:00 amRNSEBT Share Purchase
27th Jan 20267:00 amRNSHolding(s) in Company
27th Jan 20267:00 amRNSQ3 FY26 Trading Statement
15th Jan 20269:24 amRNSDirector/PDMR Shareholding
31st Dec 202511:11 amRNSTotal Voting Rights
31st Dec 202511:11 amRNSTotal Voting Rights
12th Dec 20253:00 pmRNSDirector/PDMR Shareholding
12th Dec 20257:00 amRNSDirector/PDMR Shareholding
8th Dec 20257:00 amRNSDirector/PDMR Shareholding
1st Dec 202512:35 pmRNSBlock listing Interim Review
28th Nov 202511:58 amRNSTotal Voting Rights
25th Nov 20257:00 amRNSHolding(s) in Company
20th Nov 20257:00 amRNSH1 FY26 Results
12th Nov 20252:13 pmRNSDirector/PDMR Shareholding
31st Oct 20252:37 pmRNSTotal Voting Rights
21st Oct 20256:16 pmRNSHolding(s) in Company
20th Oct 20254:06 pmRNSHolding(s) in Company
16th Oct 20252:12 pmRNSDirector/PDMR Shareholding
14th Oct 202511:51 amRNSDirector/PDMR Shareholding
10th Oct 20257:00 amRNSAppointment of joint corporate broker
9th Oct 20251:53 pmRNSDirector/PDMR Shareholding
2nd Oct 20254:20 pmRNSTotal Voting Rights
2nd Oct 20257:00 amRNS-RUAE distribution partnership and LATAM expansion
16th Sep 202511:55 amRNSDirector/PDMR Shareholding
16th Sep 20257:00 amRNSHolding(s) in Company
2nd Sep 20259:30 amRNSDirector/PCA Shareholding
29th Aug 20254:22 pmRNSTotal Voting Rights
12th Aug 20253:17 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.